Objective: Gemcitabine has been widely used, and cisplatin plus gemcitabine is considered as standard first-line chemotherapy for patients with advanced biliary tract cancer. However, no standard therapy was established following the progression to gemcitabine-containing first-line therapy. As S-1 monotherapy as second-line chemotherapy is still not well known in a practical setting this study aimed to clarify its efficacy and safety. Methods: We retrospectively reviewed 55 consecutive patients who received S-1 monotherapy as second-line chemotherapy after failure of a gemcitabine-containing regimen at our institution from September 2007 to March 2011. The inclusion criteria were preserved organ function and an Eastern Cooperative Oncology Group performance status of 0-2 and without massive ascites or pleural effusion. S-1 was administered orally twice a day at a dose of 40 mg/m 2 for 28 days, followed by 14 days of rest. Results: Fifty-one patients were selected for this analysis. The overall response rate was 4.0% and the disease control rate was 38.0%. The median survival time was 6.0 months and the median progression-free survival was 2.3 months. Adverse events were generally mild, and treatment-related death did not occur. In the subgroup analysis, overall survival was significantly shorter in the patients with peritoneal dissemination and those who had shown no response to the first-line chemotherapy (P ¼ 0.033 and 0.023, respectively). Conclusions: S-1 monotherapy as the second-line chemotherapy for patients with gemcitabine-refractory advanced biliary tract cancer is also feasible in a practical setting and its efficacy is almost the same as in the previous prospective study.
INTRODUCTION
Biliary tract refers to all routes that bile juice passes through from hepatocytes to the duodenum, including intrahepatic bile duct, extrahepatic bile duct, gall bladder and ampulla of Vater. Therefore, biliary tract cancer (BTC) includes intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder carcinoma and ampullary carcinoma. Sometimes, intrahepatic cholangiocarcinoma is classified as primary liver cancer by UICC (1) and Japanese classification (2) , but it is more often classified as BTC because of its development, as well as pathological and clinical features.
BTC is not a common disease throughout the world; however, it is more commonly encountered in East Asia and Latin America than any other countries (3) . Furthermore, it is the sixth leading cause of cancer-related death in Japan.
They are usually found in unresectable stage; however, resection surgery is the only way to cure BTC. Moreover, recurrence after curative surgery is common because BTC has high malignant potential and propensity to metastasize. Therefore, systemic chemotherapy is important for the treatment of BTC. Gemcitabine (GEM) has shown efficacy and safety for advanced BTC in many reports (4 -6) . GEM is considered the key drug for the treatment of advanced BTC, and GEM monotherapy was recognized as a community standard in Japan until 2010. In 2010, the results of the Phase III study of cisplatin (CDDP) plus GEM versus GEM for advanced BTC were reported (7) and GEM and CDDP combination therapy showed superiority to GEM monotherapy. Similar results were also reported in Japanese Phase II study (8) . CDDP and GEM combination therapy is now considered as a standard first-line regimen for advanced BTC. In 2011, CDDP received approval from social insurance in Japan for advanced BTC.
No standard therapy was established following the progression to GEM-containing first-line therapy. S-1 is an oral agent consisting of a mixture of tegafur, 5-chloro-2, 4-dihydroxypyrimidine and potassium oxonate at a molar ratio of 1:0.4:1 (9), which has mainly been investigated in Asian countries. In a Phase II study of S-1 as a drug for firstline chemotherapy for advanced BTC, it was reported that the objective response rate was 32.5%, and the median survival time (MST) was 9.4 months with median time to progression (TTP) 3.7 months (10, 11) . Because of the good anti-tumor activity, two prospective studies of S-1 monotherapy as second-line therapy after the progression to GEM (12,13) were conducted. In these studies, the objective response rates were 22.7 and 7.5% and the values of MST were 13.5 and 7.5 months. S-1 is practically used as a drug for second-line chemotherapy in Japan to treat advanced BTC.
However, these results were quite different from one another. Consequently, the efficacy and safety of S-1 monotherapy as second-line therapy for advanced BTC is still not established in a practical setting, which is why we performed this retrospective analysis.
PATIENTS AND METHODS

PATIENTS
The subjects were 55 consecutive patients who received S-1 monotherapy as second-line chemotherapy after the failure to GEM-containing regimen at Kanagawa Cancer Center between September 2007 and March 2011. We retrospectively reviewed their medical records. All the patients received a pathological and graphical diagnosis of BTC (intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer or ampullary carcinoma). Advanced BTC was defined as (i) metastasis to other organs or to a distant lymph node, (ii) metastasis to form a bulky lymph node of hepatoduodenal ligament, (iii) invasion to common hepatic artery or proper hepatic artery or celiac artery or superior mesenteric artery, (iv) invasion to the bilateral branches of hepatic artery, (v) invasion to the trunk of portal vein which leads to the growth of collateral vessels, or invasion to the bilateral branches of portal vein, (vi) invasion to the bilateral secondary branch of the bile duct, (vii) invasion to one side of the hepatic artery/portal vein and invasion to another side of the secondary branches of the bile duct and (viii) recurrence after curative surgery. In addition to these criteria, intrahepatic cholangiocarcinoma with intrahepatic metastasis in the bilateral lobe is also defined as advanced BTC. Additional criteria for this retrospective analysis included an Eastern Cooperative Oncology Group performance status (PS) of 0 -2, good bone marrow function, white blood cell count 3000/mm 3 , neutrophil count 1500/mm 3 , hemoglobin 8.5 g/dl, platelet count 100 000/mm 3 , good renal function (serum creatinine 1.5 mg/dl) and good liver function (total bilirubin 2.0 mg/dl and transaminase levels 2.5 times the upper limit of the normal ranges). Patients with obstructive jaundice were eligible after receiving adequate biliary drainage and decreasing transaminase levels (less than five times the upper limit of the normal range). Patients were excluded if they had not received GEM in the first-line regimen or had already received S-1, or if they had massive ascites, pleural effusion, active concomitant malignancy, brain metastasis, interstitial pneumonia, uncontrolled diabetes mellitus and regular use of warfarin, phenytoin or frucitocin.
TREATMENT S-1 was administered orally twice a day at a dose of 40 mg/ m 2 . The initial doses were determined according to the body surface area (BSA) calculated by body weight and height as follows: BSA , 1.25 m 2 , 80 mg/day; 1.25 m 2 BSA , 1.5 m 2 , 100 mg/day; 1.5 m 2 BSA, 120 mg/day. S-1 was given for 28 days followed by 14 days of rest. Dose reduction and interruption were considered in the case of severe toxicities (graded as 3 -4) according to the Common Terminology Criteria of Adverse Event version 4.0 (CTCAE v4.0). No dose re-escalation was conducted following the dose reduction. This treatment course was repeated until disease progression, unacceptable toxicities or patients' refusal.
EVALUATION
Tumor response was assessed approximately every 2 months in contrast-enhanced computed tomography according to the Response Evaluation Criteria In Solid Tumor (RECIST, version 1.1). Toxicities were evaluated according to the CTCAE v4.0. Overall survival was defined as the duration from the date of treatment initiation to the date of death of any cause or the last follow-up. Progression-free survival (PFS) was defined as the duration from the date of S-1 treatment initiation to the date of documented disease progression or death. The overall survival and PFS were calculated using the Kaplan -Meier method. Subgroup analyses were evaluated with the log-rank test and the Cox proportional hazard model. This study was approved by Kanagawa Cancer Center institutional review board.
RESULTS
SUBJECTS
One hundred and thirteen patients with advanced BTC received GEM monotherapy or GEM plus CDDP combination therapy as the first-line treatment and 83 patients discontinued. Among these 83 patients, 55 patients received S-1 monotherapy as the second-line treatment and 51 patients were selected for this study according to the eligibility criteria. The reason for exclusion was anemia due to the first-line treatment in one patient, massive ascites in one patient, PS 3 in one patient and patient's refusal for surgical treatment in one patient. The patient characteristics are shown in Table 1 . Among the 51 patients, the median age was 69 years (range 39 -81), 29 (57%) were male and all the patients except only one had an Eastern Cooperative Oncology Group PS of 0 -1. The number of patients with gallbladder carcinoma was 26 (51%), and that with recurrent disease after the curative surgery was 8 (16%). Regarding the first-line treatment, the number of patients who had received GEM monotherapy was 47 (92%), while the number of patients who received GEM plus CDDP combination therapy was 4 (8%). In GEM monotherapy and GEM plus CDDP combination therapy, PFS was 4.0 and 3.4 months, 5 patients (10.6%) and 1 (25%) patient showed a partial response and 26 (55.3%) and 2 (50%) showed stable disease, respectively. TREATMENT A total of 176 courses were administered, with a median of two courses per patient (range 1 -18). Dose reduction due to the adverse events was conducted in 17 (33%) patients, and treatment was interrupted during the course in 15 (29%) patients. The median dose intensity of S-1 was 87.3% (range 38.4 -100%) compared with the planned dosage. S-1 monotherapy was discontinued in 43 (84%) patients because of the disease progression and in 4 (8%) patients because of the adverse events (Grade 2 nausea in two patients, Grade 2 gastrointestinal bleeding in one and Grade 2 anorexia in one). Four patients (8%) had been receiving S-1 monotherapy at the time of this analysis.
EFFICACY
Excluding 1 patient who could not be evaluated, 2 (4.0%) patients showed partial responses and 19 (38%) showed stable disease, resulting in an overall objective response rate of 4% and a disease control rate of 42%. The overall MST was 6.0 months and the PFS was 2.3 months (Fig. 1) . In subgroup analysis according to the presence of ascites, indicating the presence of peritoneal dissemination, the MSTs of patients with and without ascites were 2.2 and 6.8 months (P ¼ 0.033), respectively. And there was a significant difference in overall survival between patients who had progressive disease against the first-line chemotherapy and who had any response (3.5 and 7.2 months, respectively, P ¼ 0.023). These two factors were also significant in multivariate analysis; the hazard ratios were 3.2 and 2.3, respectively. However, there was no significant difference between gallbladder carcinoma and non-gallbladder carcinoma ( Table 2 ). Table 3 presents the adverse events that occurred during the S-1 monotherapy as the second-line treatment. No treatment 802 S-1 as second-line treatment for biliary tract cancer death occurred, and generally, toxicities were mild: Grade 3/4 hematologic adverse events, which include anemia, leukopenia, neutropenia and thrombocytopenia, were observed in only one patient for each, and non-hematologic adverse events with Grade 3/4 were diarrhea (three patients, 6%), anorexia (one patient, 2%), nausea (one patient, 2%), mucositis oral (one patient, 2%) and rash (one patient, 2%).
TOXICITIES
DISCUSSION
In this analysis, 64% of the patients received second-line chemotherapy after being refractory to GEM-containing regimen similar to 70% of the patients who received the second-line chemotherapy in the past study (8) . These findings indicate that the development of effective second-line chemotherapy is critical to the treatment of advanced BTC. However, there is no standard regimen after the refractory condition to the GEM plus CDDP regimen, as National Comprehensive Cancer Network guideline shows no recommendation about it. 5-Fluorouracil (5-FU) was expected to have an anti-tumor effect for advanced BTC, and some studies of 5-FU monotherapy or 5-FU combination regimen as first-line treatment were reported previously (14 -19) . According to these studies, it is considered that 5-FU was ineffective as an agent for first-line treatment. S-1, which is a 5-FU derivative, is a promising agent for first-line treatment (10, 11) . However, the agent effective in the first-line treatment is not always effective in the second-line treatment, and it is necessary to evaluate the efficacy and safety of the agent in the second-line treatment. The results of the current study were similar to the report published by Suzuki et al. (13) at the 2010 annual meeting of the American Society of Clinical Oncology. On the other hand, the results reported by Sasaki et al. (12) were largely better than those of the current study. One of the reasons for the difference may be the patient's characteristics, especially the primary site of tumor and peritoneal dissemination. It was reported that gallbladder cancer has a poor prognosis (6, 20) . Gallbladder cancer was included 51% in the current study, while only 27% in the Phase II study reported by Sasaki et al. (12) . As for the peritoneal dissemination, it was not mentioned in the report so it cannot be compared. Instead, they insisted on the tumor volume rather than on the primary site. From this point of view, patients with recurrent disease show better prognosis than those with non-resectable disease because careful observation results in small tumor volume when the recurrence is pointed out (8) . However, no survival difference was observed between the patients with recurrent disease and non-resectable disease in our study, and since the outcome that recurrent case had better prognosis may mean lead time bias, further studies are needed to address this issue.
Subgroup analysis of our study indicates that patients who had shown progressive disease for the first-line chemotherapy administering GEM tended to have worse prognosis despite the second-line chemotherapy of S-1 than those who had shown disease control. It means that S-1 monotherapy as second-line treatment may not salvage patients who did not show any response to the GEM-containing regimen. Neither GEM nor CDDP cross-reacts with S-1 in pharmacokinetics (21 -25) , and patients who showed disease progression against both first-line and second-line chemotherapy may have other complex factors. Nonetheless, it is important to exercise caution while interpreting the results of this retrospective study, as the patients' backgrounds are different from one another.
Concerning the toxicities, Grade 3 -4 adverse events were not frequent and no treatment-related death was observed. Moreover, treatment discontinuation was needed for only four (8%) patients. Therefore, two prospective studies and the current study showed similar results, indicating that S-1 monotherapy is tolerable in the second-line treatment after the GEM failure. Other treatment regimens were reported for the patients with BTC refractory to GEM (Table 4) . Lee et al. (26) reported that the Conti-FAM regimen showed a response rate of 12% and an MST of 6.7 months with a TTP of 2.3 months. Pino et al. (27) reported that the CapCel regimen showed a response rate of 9% and an MST of 4.4 months with a PFS of 4.0 months. These studies suggest modest efficacy and safety; however, it is a problem that these studies included more patients with pancreatic cancer rather than with BTC. Recently, many molecular-targeting drugs are developed, and some of these are expected to be efficacious for advanced BTC. Paule et al. suggested the efficacy of the cetuximab plus GEM-oxaliplatin (GEMOX) regimen for patients who are refractory to GEMOX (28) . The study enrolled a few patients and was limited to intrahepatic cholangiocarcinoma. However, cetuximab plus GEMOX was expected to be useful for the first-line treatment in the single-arm Phase II study (29) , and cetuximab plus GEMOX will be one of the candidates for the standard care of secondline treatment after the GEM plus platinum. Lastly, sunitinib is also expected in the second-line treatment (30) .
Brandi (31) analyzed EM plus platinum compound, capecitabine or irinotecan as a drug for second-line treatment for patients refractory to GEM in the first-line treatment. It asks the clinical questions whether or not GEM should be used in the second-line treatment for patients refractory to GEM in the first-line treatment. Indeed, 5-FU is the key drug in metastatic colorectal cancer, which should be used after failure to firstline regimen including itself (32, 33) . In advanced BTC, some clinical trials that investigate the usefulness of GEM-containing second-line treatment after the failure to GEM are ongoing in Japan, such as GEMOX (UMIN000003650) and fix-dose rate GEM plus S-1(UMIN000005918).
The efficacy of second-line chemotherapy by S-1 monotherapy and these reported regimens should be evaluated by placebo control studies because the result will change 804 S-1 as second-line treatment for biliary tract cancer because of the patient's background. Nevertheless, it is difficult to carry out a randomly controlled study, which compares S-1 monotherapy with placebo, since S-1 is approved for advanced biliary tract cancer by social insurance in Japan. Therefore, S-1 monotherapy can be the control arm in the clinical trials that test new promising regimens in the future.
In conclusion, S-1 monotherapy in a practical setting is well tolerated, and its efficacy is almost the same as the prospective clinical trials for patients with advanced BTC refractory to a GEM-containing regimen. Further development and randomized controlled studies of the second-line treatment are warranted. Conti-FAM; continuous 5-fluorouracil, doxorubicin and mitomycin-C; CapCel, capecitabine and celecoxib; GEMOX, gemcitabine and oxaliplatin; Cet, cetuximab; GEM, gemcitabine; CPT-11, irinotecan; GBC, gallbladder carcinoma; TTP, time to progression PFS; progression free survival.
